Alkermes plc (ALKS)
Nasdaq: ALKS · Pharmaceutical Preparations · Dublin 4, IE · filing with the SEC since 2011
Grade6.6
◀ Past 6.8● Present 7.2▶ Future 5.4
Who owns Alkermes plc
As filed with the SECHolders of 5% or more
5
Blackrock, Inc. holds 15.8% of Common Stock, as its SCHEDULE 13G/A filed Apr 28, 2025 says.
Directors and officers
16
report now, of 32 people on the record since 2011. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 28, 2025 · Common Stock
Baker Bros. Advisors LP
SCHEDULE 13G · filed Feb 17, 2026 · Ordinary Shares, $0.01 per share
Vanguard Portfolio Management
SCHEDULE 13G · filed Apr 28, 2026 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 28, 2026 · Common Stock
State Street Corporation
SCHEDULE 13G · filed Nov 10, 2025 · COMMON STOCK · 4.9% in May 13, 2025
Wellington Management Group LLP
SCHEDULE 13G/A · filed Feb 10, 2025 · Common Stock · reported falling below 5%
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed May 15, 2026 · COMMON STOCK · reported falling below 5%, from 6.1% in Aug 14, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What ALKS reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Mural Oncology plc
An entity · legal entity · owns, named in the 10-K filed Feb 25, 2026
Avadel Pharmaceuticals Plc
A company bought · acquisition · owns, named in the 10-K filed Feb 25, 2026
20 subsidiaries in 4 countries, from the list filed with the 10-K filed Feb 25, 2026.
Insider tradesForm 4
33sales
0purchases
31sales on a scheduled plan
7people selling
$10.1Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 3, 2025 to Nov 3, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 3, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 32 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 15 | $3.7M | 15 | 0 | $0 |
| Snyderman Nancy Lynn Md | director | 1 | $2.2M | 0 | 0 | $0 |
| Cooke Shane | President, Alkermes plc | 2 | $2.1M | 2 | 0 | $0 |
| Parisi Samuel Joseph | VP, Finance (Interim PAO) | 2 | $900,000 | 1 | 0 | $0 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 10 | $800,000 | 10 | 0 | $0 |
| Nichols Christian Todd | SVP, Chief Commercial Officer | 3 | $600,000 | 3 | 0 | $0 |
| Wright Christopher I | director | 1 | $100,000 | 1 | 0 | $0 |